You are here: Home » Current Affairs » Coronavirus » News
Business Standard

PGI Rohtak to start phase-2 trial of Bharat Biotech's Covid-19 vaccine

Post Graduate Institute (PGI) Rohtak will start the phase-2 human clinical trial of Bharat Biotech's COVID-19 vaccine

Topics
Coronavirus Vaccine | Bharat Biotech

ANI  |  General News 

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Representative image

Post Graduate Institute (PGI) Rohtak will start the phase-2 human clinical trial of Bharat Biotech's COVID-19 vaccine.

Speaking to ANI, Dr OP Kalra, vice-chancellor, PGI Rohtak said, "We got permission from to start a phase-2 human clinical trial of their vaccine. We've 300 volunteers, aged between 12 years and 65- years, out of which screening of 15 has been completed."

"We hope to get vaccine dosages by tomorrow morning," added Kalra.

Recently, Niti Aayog member Dr Vinod K Paul said that Bharat Biotech's vaccine candidate based on inactivated virus procured by ICMR and Zydus Cadila's candidate based on viral DNA are two Indian COVID-19 vaccines in second phase trial.

"In India, Bharat Biotech's vaccine candidate based on inactivated virus procured by ICMR is in the Phase II trial along with Zydus Cadila's candidate which is based on viral DNA. The Oxford vaccine candidate developed by Serum Institute of India is already in Phase III trial in Maharashtra and some other States," he said.

The total coronavirus cases in the country reached 42,04,614 including 8,82,542 active cases, 32,50,429 cured/discharged/migrated and 71,642 deaths, as per the data from the Ministry of Health and Family Welfare.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, September 08 2020. 09:50 IST
RECOMMENDED FOR YOU
.